Dr. Mehran Jamali, MD

Dr. Jamali practices at San Francisco Healthcare & Wellness Center in Placentia, California.

Dr. Jamali's NPI, 1356874143, was assigned on April 7, 2017. Dr. Jamali holds California license A170059.

Dr. Jamali's primary practice is San Francisco Healthcare & Wellness Center, at 377 E Chapman Ave, Placentia, CA 92870 in Orange County. The practice phone is (415) 563-0565.

Dr. Jamali's primary practice is San Francisco Healthcare & Wellness Center in Placentia, California. Dr. Jamali is also affiliated with Stanford Hospital at 300 Pasteur Drive. The medical group on file is Quantum Bay Area Hospitalist Medical Group Inc. Dmand AI also links Dr. Jamali to 5 more skilled nursing facilities, 3 home health agencies, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jamali practices, 11 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Jamali's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Jamali is licensed in California.

CMS data shows 6,484 Medicare services from Dr. Jamali across 5 procedure codes in 2024, for 1,117 Medicare patients. Medicare paid $543,695 for them.

CMS counts 1,117 Medicare patients who saw Dr. Jamali in 2024. The largest group is 85 and over, with 404 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 46% are also on Medicaid. Their average risk score is 2.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jamali's median patient age at 77, with 52% women.

In 2024, Dr. Jamali wrote 27,550 Medicare Part D claims for 803 patients. 88% of them were for generic drugs. CMS names the drug for 26,609 of them, across 228 drugs with 11 or more claims each, at $1,263,222 in total drug cost. In 2023, CMS named 17,243 claims across 201 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 15 out of 100 for Dr. Jamali for performance year 2024, reported individually. Dr. Jamali accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 22 papers to Dr. Jamali, published from 2014 to 2022. 2016 was the busiest year, with 5. The most frequent topics are Positron Emission Tomography Computed Tomography, Biological Transport and Multimodal Imaging. Dr. Jamali has published most often in Clin Nucl Med. Dr. Jamali's most frequent co-authors are Amir Barkhodari, MD, Andrei Horia Iagaru, MD and Erik Supratik Mittra, MD, PhD.

Dmand AI links Dr. Jamali to 1 clinical trial. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 3 general payments to Dr. Jamali from 2 drug and device companies from 2018 to 2023. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $206.